third-quarter earnings rose, thanks to nearly a 12% jump in year-over-year sales, reflecting, among other things, a strong launch for rheumatoid arthritis treatment Humira.
Abbott earned $761.2 million, or 48 cents a share, on sales of $4.85 billion in the latest quarter, compared with earnings of $720.1 million, or 46 cents a share, on sales of $4.34 billion last year. Excluding some charges, Abbott earned $835.3 million, or 53 cents a share, in the latest quarter compared with $751.6 million, or 48 cents a share, last year.
Before charges, analysts surveyed by Thomson First Call were forecasting earnings of 53 cents a share on sales of $4.71 billion in the latest quarter.
U.S. pharmaceuticals sales jumped 20% in the quarter to $1.29 billion, while international sales rose 13.2% to $1.36 billion. Three percentage points of the overall sales gain was attributable to currency translation, the company said.
Abbott closed Wednesday unchanged at $41.95.